We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+6.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$150M
AUM Growth
-$10.7M
(-6.6%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-7.61%
Top 10 Holdings %
Top 10 Hldgs %
46.24%
Holding
65
New
12
Increased
10
Reduced
12
Closed
16
Avg Time Held
3.4
quarters
Top 10 Avg Time Held
2.2
quarters
Top 20 Avg Time Held
3.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$3.24M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$3.07M |
| 3 |
Ocular Therapeutix
OCUL
|
+$2.58M |
| 4 |
MacroGenics
MGNX
|
+$2.53M |
| 5 |
Neurogene
NGNE
|
+$2.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sage Therapeutics
SAGE
|
+$5.29M |
| 2 |
Assertio
ASRT
|
+$4.53M |
| 3 |
Geron
GERN
|
+$3.87M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$3.38M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$2.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.89% |
| 2 | Miscellaneous | 8.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PRTK
26
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.04M | 1.36% |
+146,700
| New | +$2.16M |
2016 Q2
0 quarters
|
|
|
NBRV
27
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $2.02M | 1.35% |
1,080
-15
| -1% | -$30.2K |
2015 Q4
2 quarters
|
|
|
28
Neurogene
NGNE
$431M
| $1.95M | 1.3% |
+14,750
| New | +$2.34M |
2016 Q2
0 quarters
|
|
29
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $1.94M | 1.3% |
50,000
-10,000
| -17% | -$416K |
2015 Q2
4 quarters
|
|
|
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
| $1.93M | 1.29% |
240,000
| – | – |
2015 Q2
4 quarters
|
|
|
TRIL
31
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.75M | 1.17% |
195,000
| – | – |
2014 Q4
6 quarters
|
|
32
Seres Therapeutics
MCRB
$25.4M
| $1.67M | 1.12% |
+2,875
| New | +$1.69M |
2016 Q2
0 quarters
|
|
33
CytomX Therapeutics
CTMX
$508M
| $1.63M | 1.09% |
+160,000
| New | +$1.82M |
2016 Q2
0 quarters
|
|
34
Tonix Pharmaceuticals
TNXP
$105M
| – | – |
0
| – | – |
2015 Q2
4 quarters
|
|
35
DELISTED
Affimed
AFMD
| $1.48M | 0.99% |
59,500
-1,500
| -2% | -$54.8K |
2015 Q2
4 quarters
|
|
|
INNL
36
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $1.46M | 0.98% |
+265,000
| New | +$2.17M |
2016 Q2
0 quarters
|
|
37
DELISTED
Altamira Therapeutics Ltd
CYTO
| $1.43M | 0.95% |
4
| – | – |
2015 Q2
4 quarters
|
|
|
38
Ocular Therapeutix
OCUL
$1.59B
| $1.29M | 0.86% |
+260,000
| New | +$2.58M |
2016 Q2
0 quarters
|
|
39
DELISTED
Kineta, Inc. Common Stock
KA
| $1.27M | 0.85% |
+750
| New | +$1.37M |
2016 Q2
0 quarters
|
|
|
CORI
40
DELISTED
Corium International, Inc.
CORI
| $1.25M | 0.83% |
360,000
| – | – |
2015 Q4
2 quarters
|
|
41
Tenax Therapeutics
TENX
$59.9M
| $1.19M | 0.79% |
15
-1
| -6% | -$83.4K |
2014 Q4
6 quarters
|
|
42
TG Therapeutics
TGTX
$8.32B
| $1.06M | 0.71% |
175,000
-240,000
| -58% | -$1.95M |
2015 Q3
3 quarters
|
|
43
DELISTED
Evoke Pharma
EVOK
| $891K | 0.6% |
903
| – | – |
2014 Q1
9 quarters
|
|
|
NDRM
44
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $853K | 0.57% |
52,500
+14,000
| +36% | +$236K |
2016 Q1
1 quarter
|
|
45
DELISTED
Cidara Therapeutics
CDTX
| $443K | 0.3% |
+2,150
| New | +$520K |
2016 Q2
0 quarters
|
|
|
ADAP
46
DELISTED
Adaptimmune Therapeutics
ADAP
| $326K | 0.22% |
40,000
-135,300
| -77% | -$1.27M |
2016 Q1
1 quarter
|
|
47
BioLineRX
BLRX
$10.8M
| $223K | 0.15% |
417
| – | – |
2013 Q4
10 quarters
|
|
48
Aclaris Therapeutics
ACRS
$511M
| – | – |
-18,000
| Closed | -$341K | – |
|
|
49
DELISTED
Assertio
ASRT
| – | – |
-5,417
| Closed | -$4.53M | – |
|
|
50
Geron
GERN
$771M
| – | – |
-1,325,000
| Closed | -$3.87M | – |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q2 2016 Portfolio in Review
As of Q2 2016, Opaleye Management held 65 positions worth $150M, down 6.6% from $160M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Opaleye Management withdrew a net $11.4M in Q2 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was Sage Therapeutics, an estimated $5.29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.29M.
- Opaleye Management's largest Q2 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 200,000 shares worth $3.29M.
- Opaleye Management added most to Aevi Genomic Medicine Inc in Q2 2016, an estimated $2.06M increase.
- Opaleye Management's biggest Q2 2016 reduction was Ultragenyx Pharmaceutical, cutting an estimated $2.91M.
- Opaleye Management fully exited Sage Therapeutics in Q2 2016, selling an estimated $5.29M.
- Opaleye Management's ten largest holdings make up 46% of its $150M portfolio in Q2 2016.
- Opaleye Management opened 12 new positions and closed 16 in Q2 2016.
- Opaleye Management's portfolio value fell 6.6% quarter-over-quarter to $150M.
Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.